PS1-2 First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC

U31402-A-U102 is an ongoing study of HER3-DXd in NSCLC. Here, with a 23-month median follow-up, we present the first report of median overall survival (OS) for patients (pts) with EGFRm NSCLC after failure of prior EGFR TKI and platinum-based chemotherapy (PBC) treated with HER3-DXd 5.6 mg/kg IV Q3W. Other efficacy and safety measures are updated to include new data from cohort 3.